A Study to Evaluate the Lipid Regulating Effects of TRIA-662

NCT00758303 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipidemia

Interventions

DRUG: Low Dose TRIA-662
DRUG: High Dose TRIA-662
DRUG: Placebo for TRIA-662

Sponsor

Cortria Corporation